SCHEMBL1579989

SCHEMBL1579989

CN1CCN(c2cc(C=Cc3ccccc3)c(C(F)(F)F)nn2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 3/20 0.43
KDM4E B2RXH2 2/20 0.41
GLA P06280 1/20 0.41
ALK Q9UM73 2/20 0.41
CSNK1D P48730 1/20 0.41
MAPK14 Q16539 1/20 0.41
PLK4 O00444 2/20 0.41
AURKA O14965 2/20 0.41
ABL1 P00519 2/20 0.41
NTRK1 P04629 2/20 0.41
LCK P06239 2/20 0.41
CSF1R P07333 2/20 0.41
RET P07949 2/20 0.41
KIT P10721 2/20 0.41
FGFR1 P11362 2/20 0.41
SRC P12931 2/20 0.41
PDGFRA P16234 2/20 0.41
TYK2 P29597 2/20 0.41
KDR P35968 2/20 0.41
FLT3 P36888 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1579987 1.00 HRH4 (0.43) HRH4KDM4EGLAALKCSNK1D
SCHEMBL1579973 0.85 ADRB1 (0.41) KDM4ECSNK1DMAPK14CYP1A2CYP2C19
SCHEMBL1579976 0.85 ADRB1 (0.41) KDM4ECSNK1DMAPK14CYP1A2CYP2C19
SCHEMBL12635639 0.81 CKS1B (0.47) KITMAP4K4
SCHEMBL1579220 0.80 HSD11B1 (0.43) KDM4EALDH1A1
SCHEMBL1579223 0.80 HSD11B1 (0.43) KDM4EALDH1A1
SCHEMBL1579606 0.80 ALDH1A1 (0.44) KDM4ERETCYP1A2CYP2C19SMN1; SMN2
SCHEMBL1579604 0.80 ALDH1A1 (0.44) KDM4ERETCYP1A2CYP2C19SMN1; SMN2
SCHEMBL12671687 0.76 HRH4 (0.46) HRH4CSNK1DMAPK14CYP1A2CYP2C19
SCHEMBL1579440 0.75 BPTF (0.43) CSNK1DMAPK14CYP1A2CYP2C19ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8530474-B2 Substituted 6-(1-piperazinyl)-pyridazines as 5-HT6 receptor antagonists JANSSEN PHARMACEUTICA NV (BE) 2013-09-10 US disclosed
EP-2310374-B1 SUBSTITUTED 6- (1-PIPERAZINYL) -PYRIDAZINES AS 5-HT6 RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2012-10-31 EP disclosed
US-20110112107-A1 SUBSTITUTED 6-(1-PIPERAZINYL)-PYRIDAZINES AS 5-HT6 RECEPTOR ANTAGONISTS JANSSEN-CILAG S.A. (ES) 2011-05-12 US disclosed
EP-2310374-A1 SUBSTITUTED 6- (1-PIPERAZINYL) -PYRIDAZINES AS 5-HT6 RECEPTOR ANTAGONISTS Janssen Pharmaceutica N.V. (BE) 2011-04-20 EP disclosed
WO-2010000456-A1 SUBSTITUTED 6- (1-PIPERAZINYL) -PYRIDAZINES AS 5-HT6 RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112107-A1 SUBSTITUTED 6-(1-PIPERAZINYL)-PYRIDAZINES AS 5-HT6 RECEPTOR ANTAGONISTS HTR6, HTR5A, HTR1A HRH4 60/4885KDM4E 2840/4885GLA 4703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.